Healthcare >> CEO Interviews >> November 17, 2008
MICHAEL D. KISHBAUCH, President and Chief Executive Officer of Achillion
Pharmaceuticals, Inc., joined Achillion as President and CEO in July 2004. He
has had an impressive record of launching and commercializing products over his
20 years of pharmaceutical industry experience. Prior to leading Achillion
through its initial public offering in 2006, Mr. Kishbauch founded OraPharma,
Inc., an emerging pharmaceutical company focused on oral health. In less than
seven years, Mr. Kishbauch and his team completed clinical development and
launched OraPharma's lead product, successfully took the company public, and
ultimately sold the company to Johnson & Johnson in February 2003. Previously,
Mr. Kishbauch spent several years as President and COO of MedImmune, Inc., a
top-tier biotechnology company focused on infectious disease and cancer. Prior
to that, he served as Vice President and senior product marketing executive for
Ciba-Geigy, where he oversaw the launches of two products, which at the time
were the two most successful product launches in industry history as measured by
first-year sales. Mr. Kishbauch began his career with The Procter and Gamble
Company, received a BA in Biology from Wesleyan University, and an MBA from the
Wharton School of the University of Pennsylvania. Profile
Mr. Kishbauch: Achillion is a New Haven-based biotech that is focused squarely
on infectious disease. We are located right on the
